Breakthrough in breast cancer treatment? BriaCell Therapeutics shares soar 150%!
BriaCell Therapeutics Corp., a clinical-stage biotechnology company, saw its shares surge by more than 150% to $1.55 following the release of positive overall survival data ... Read More
BriaCell Therapeutics gets license for anti-cancer agent sCD80 from UMBC
BriaCell Therapeutics has signed an exclusive licensing deal with the University of Maryland, Baltimore County (UMBC) to develop and commercialize Soluble CD80 (sCD80) as a ... Read More
BriaCell Therapeutics’ Bria-IMT gets FDA fast track status in breast cancer
BriaCell Therapeutics has secured the fast track status from the US Food and Drug Administration (FDA) for its lead candidate — Bria-IMT for the treatment ... Read More